Unknown

Dataset Information

0

Adenosine-A1 receptor agonist induced hyperalgesic priming type II.


ABSTRACT: We have recently shown that repeated exposure of the peripheral terminal of the primary afferent nociceptor to the mu-opioid receptor (MOR) agonist DAMGO ([D-Ala, N-Me-Phe, Gly-ol]-enkephalin acetate salt) induces a model of transition to chronic pain that we have termed type II hyperalgesic priming. Similar to type I hyperalgesic priming, there is a markedly prolonged response to subsequent administration of proalgesic cytokines, prototypically prostaglandin E2 (PGE2). However, type II hyperalgesic priming differs from type I in being rapidly induced, protein kinase A (PKA), rather than PKC? dependent, not reversed by a protein translation inhibitor, occurring in female as well as in male rats, and isolectin B4-negative neuron dependent. We report that, as with the repeated injection of a MOR agonist, the repeated administration of an agonist at the A1-adenosine receptor, also a Gi-protein coupled receptor, N-cyclopentyladenosine (CPA), also produces priming similar to DAMGO-induced type II hyperalgesic priming. In this study, we demonstrate that priming induced by repeated exposure to this A1-adenosine receptor agonist shares the same mechanisms, as MOR-agonist induced priming. However, the prolongation of PGE2 hyperalgesia induced by repeated administration of CPA depends on G-protein ?i subunit activation, differently from DAMGO-induced type II priming, in which it depends on the ?/? subunit. These data implicate a novel form of Gi-protein signaling pathway in the type II hyperalgesic priming induced by repeated administration of an agonist at A1-adenosine receptor to the peripheral terminal of the nociceptor.

SUBMITTER: Araldi D 

PROVIDER: S-EPMC5048916 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Adenosine-A1 receptor agonist induced hyperalgesic priming type II.

Araldi Dioneia D   Ferrari Luiz F LF   Levine Jon D JD  

Pain 20160301 3


We have recently shown that repeated exposure of the peripheral terminal of the primary afferent nociceptor to the mu-opioid receptor (MOR) agonist DAMGO ([D-Ala, N-Me-Phe, Gly-ol]-enkephalin acetate salt) induces a model of transition to chronic pain that we have termed type II hyperalgesic priming. Similar to type I hyperalgesic priming, there is a markedly prolonged response to subsequent administration of proalgesic cytokines, prototypically prostaglandin E2 (PGE2). However, type II hyperalg  ...[more]

Similar Datasets

| S-EPMC5474187 | biostudies-literature
| S-EPMC3285310 | biostudies-literature
| S-EPMC5908744 | biostudies-literature
| S-EPMC7887845 | biostudies-literature
| S-EPMC10341625 | biostudies-literature
| S-EPMC5830512 | biostudies-literature
| S-EPMC9408941 | biostudies-literature
| S-EPMC3838692 | biostudies-literature
| S-EPMC4272367 | biostudies-literature
| S-EPMC6697398 | biostudies-literature